<DOC>
	<DOCNO>NCT00435838</DOCNO>
	<brief_summary>This retrospective observational study follow CNA106030 ( study evaluate whether prospective genetic screen HLA-B*5701 reduce incidence hypersensitivity reaction abacavir ) . This study aim collect data approximately 35 subject withdraw CNA106030 find HLA-B*5701 positive . HIV disease management adverse event data subject , risk/benefit ratio treatment abacavir may alter subsequent prescribing , collect</brief_summary>
	<brief_title>A Study Patient Management HIV-1 Infected Patients Found Have Genetic Marker HLA-B*5701</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Subjects receive notification receive abacavir CNA106030 study positive HLAB*5701 screen result , subsequently withdraw protocol CNA106030 . Subjects willing able understand provide write informed consent prior participation study . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Exclusion criterion : Subjects enrol CNA106030 study Subjects HLAB*5701 positive Subjects consent tell HLAB*5701 status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HLa-B*5701 Abacavir</keyword>
</DOC>